<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158064">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01901393</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-020</org_study_id>
    <nct_id>NCT01901393</nct_id>
  </id_info>
  <brief_title>Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Double-blind Study to Determine the Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of intravenous ibuprofen compared to
      ketorolac for the treatment of postoperative pain as measured by patient pain intensity
      (Visual Analog Scale, VAS)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of Pain Relief</measure>
    <time_frame>First possible time post-surgery, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain assessed using VAS (Visual Analog Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use in post-operative period</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amount of rescue med (in mg) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first use of rescue med will be measured</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using 2 question, 4 point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg ibuprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30mg ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV ibuprofen</intervention_name>
    <arm_group_label>IV ibuprofen</arm_group_label>
    <other_name>Caldolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <arm_group_label>ketorolac</arm_group_label>
    <other_name>Ketorolac Tromethamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for knee arthroscopy

        Exclusion Criteria:

          -  Inadequate IV access.

          -  History of allergy or hypersensitivity to any component of ibuprofen, ketorolac,
             aspirin (or aspirin related products), NSAIDs, opioids or COX-2 inhibitors.

          -  Less than 18 years of age.

          -  Use of analgesics less than 8 hours prior to surgery.

          -  Patients with active, clinically significant anemia.

          -  History or evidence of asthma or heart failure.

          -  Pregnant.

          -  Recent history of chronic opioid use.

          -  Concomitant use of probenecid.

          -  Inability to understand the requirements of the study, be willing to provide written
             informed consent (as evidenced by signature on an informed consent document approved
             by an Institutional Review Board [IRB]), and agree to abide by the study restrictions
             and to return for the required assessments.

          -  Refusal to provide written authorization for use and disclosure of protected health
             information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur P Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Rock, PhD</last_name>
    <phone>6152550068</phone>
    <email>arock@cumberlandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Byron Kaelin, RN</last_name>
    <phone>6152550068</phone>
    <email>bkaelin@cumberlandpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shrock Orthopedic Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Shrock, ARNP</last_name>
      <phone>954-626-3743</phone>
      <email>Natalie@shrockresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin B Shrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahendrakumar Shah, MD</last_name>
      <phone>312-942-1982</phone>
      <email>Mahendrakumar_Shah@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Bernard R Bach, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Sports Medicine &amp; Orthopaedic Clinic</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Inman, LPN</last_name>
      <phone>662-840-5856</phone>
    </contact>
    <investigator>
      <last_name>Stephen Southworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Vexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Otey</last_name>
      <phone>614-366-1943</phone>
      <email>Fernando.Arbona@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Fernando Arbona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post Operative Pain,</keyword>
  <keyword>Pail relief</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
